Transaction #23720 · Form 4 · 0001867539-25-000006
Vor Biopharma Inc. · Stock award · Stock Option (Right to Buy)
Vor Biopharma Inc. · Transacted December 18, 2025 · Filed December 19, 2025
What does this filing report?
An SEC Form 4 filing for Vor Biopharma Inc. records a stock award involving Stock Option (Right to Buy) on December 18, 2025. The reported quantity was 3,000. The filing date is December 19, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Vor Biopharma Inc.
- Company CIK
- 0001817229
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 3,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 3,000
- Ownership description
- Not reported
- SEC acceptance time
- Dec 19, 2025, 6:14 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Levin Andrew David ↗
Director
CIK 0001867539
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 3,000
- Conversion / exercise price
- 12.8
- Exercise date
- Not reported
- Expiration date
- December 17, 2035
Filing footnotes & remarks
- F1
- The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on December 18, 2025, in each case subject to the Reporting Person's continued service as of each such date.
- F2
- Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.